Sumsuzzman D M, Wang Z, Langley JM, Moghadas SM, Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: A systematic review and meta-analysis, The Lancet Child & Adolescent Health 2025, 9: 393-403.
Du Z, Pandey A, Moghadas SM, Bai Y, Wang L, Matrajt L, Singer BH, Galvani AP, Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults, Nature Medicine 2025, 31(2): 647-652.
Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clinical Infectious Diseases. 2024, 78(5): 1328-1335.
Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM, Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: A simulation study, The Lancet Regional Health - Americas 2023, 28: 100629.
Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP, The implications of silent transmission for the control of COVID-19 outbreaks, Proceedings of the National Academy of Sciences USA 2020, 117(30): 17513–17515.
For citation of our published studies, visit Google Scholar
Wells CR, Pandey A, Ye Y, Bawden CE, Giglio R, Wong C, Wang V, Cipriano C, Ayaz L, Röst G, Moghadas SM, Fitzpatrick MC, Chokshi DA, Singer BH, Galvani AP, The health and economic repercussions of declining MMR coverage in the United States, Proceedings of the National Academy of Sciences USA 2026 (in press).
Sumsuzzman DM, Shi C, Moghadas SM, Real-world effectiveness of RSVpreF and RSVpreF3 in preventing hospitalisation and emergency department visits associated with respiratory syncytial virus in older adults: a meta-analysis, Clinical Infectious Diseases 2026 (in press).
Sumsuzzman DM, Shi C, Langley JM, Moghadas SM, Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis, JAMA Pediatrics 2026, 180(2): 152-159.
Wells CR, Shoukat A, Shin T, Galvani AP, Moghadas SM, Racial and ethnic disparities in meningococcal vaccination coverage and disease burden among U.S. adolescents, Journal of Adolescent Health 2026, 78(2): 308-314.
Fitzpatrick MC, Wells CR, Pandey A, Ayaz L, Singer BH, Hotez PJ, Moghadas SM, Galvani AP, School-level gaps in MMR coverage as the fuel for measles outbreaks, Annals of Internal Medicine 2026, 179: 149-152.
Abdollahi E, Moghadas SM, Galvani AP, The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study, Journal of Clinical Tuberculosis and other Mycobacterial Diseases 2025, 41: 100569.
Krylov SN, Krylova SM, Le ATH, Moghadas SM, Mawani A, Tabatabaei N, Papagelis M, Tsasis P, Wiktorowicz ME, Rosenbaum RS, A policy roadmap for sustainable mass-testing, Health Affairs Scholar 2025, 3(8): qxaf151.
Sumsuzzman D M, Wang Z, Langley JM, Moghadas SM, Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: A systematic review and meta-analysis, The Lancet Child & Adolescent Health 2025, 9: 393-403.
Shi C, Ferreira SC, Maia HP, Moghadas SM, The impact of information dissemination and behavioural responses on epidemic dynamics: A multi-layer network analysis, Infectious Disease Modelling 2025, 10: 960-978.
Sumsuzzman D Md, Ye Y, Wang Z, Pandey A, Langley JM, Galvani AP, Moghadas SM, Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: A global systematic review and meta-analysis, BMC Infectious Diseases 2025, 25, 215.